Literature DB >> 15957086

Schizophrenia: etiology and pharmacotherapy.

M R Mohammadi1, S Akhondzadeh.   

Abstract

Schizophrenia is one of the major psychiatric disorders. Psychosis, in its narrow definition, is restricted to delusions or hallucinations in the absence of insight into their pathological nature. Impairment in psychosocial function is an essential feature of schizophrenia. Research in the last decade has confirmed that schizophrenia is a brain disorder that cannot be attributed solely to psychosocial factors. It is widely accepted from twin and adoption studies that schizophrenia has a significant genetic component. In addition, it is a general belief that schizophrenia is caused by a biological abnormality, even though all attempts to identify that abnormality have been unsuccessful. A major landmark in the history of the understanding and treatment of schizophrenia was the discovery that dopamine D2-blocking agents can control the hallucinations and delusions of schizophrenic patients. However, clinicians have noticed that classical antipsychotics are generally ineffective against the negative symptoms that are prominent in patients with a chronic course. In this article, we will focus on the etiology and pharmacotherapy of schizophrenia.

Entities:  

Year:  2001        PMID: 15957086

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  6 in total

1.  A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.

Authors:  Mohammad Arbabi; Mohaddeseh Bagheri; Farzin Rezaei; Seyyed-Ali Ahmadi-Abhari; Mina Tabrizi; Farahnaz Khalighi-Sigaroudi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

2.  Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Authors:  Shahin Akhondzadeh; Raofeh Ghayyoumi; Farzin Rezaei; Bahman Salehi; Amir-Hossein Modabbernia; Azad Maroufi; Gholam-Reza Esfandiari; Mehrangiz Naderi; Fariba Ghebleh; Mina Tabrizi; Shams-Ali Rezazadeh
Journal:  Psychopharmacology (Berl)       Date:  2010-10-15       Impact factor: 4.530

3.  Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial.

Authors:  S Akhondzadeh; M Noroozian; M Mohammadi; S Ohadinia; A H Jamshidi; M Khani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

4.  Effect of plant extracts on Alzheimer's disease: An insight into therapeutic avenues.

Authors:  M Obulesu; Dowlathabad Muralidhara Rao
Journal:  J Neurosci Rural Pract       Date:  2011-01

5.  The effectiveness of computerized cognitive rehabilitation training program in improving cognitive abilities of schizophrenia clients.

Authors:  Mohammad Reza Mohammadi; Zahra Keshavarzi; Siavash Talepasand
Journal:  Iran J Psychiatry       Date:  2014-10

6.  Comparison of Plasma Neurosteroid and Prolactin Levels in Patients with Schizophrenia and Healthy Individuals.

Authors:  Forough Riahi; Maryam Izadi-Mazidi; Ali Ghaffari; Elham Yousefi; Shahram Khademvatan
Journal:  Scientifica (Cairo)       Date:  2016-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.